COVID-19 Vaccines and Vaccination
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of this “COVID-19 vaccines and vaccination” special issue is to provide with information on currently available and novel experimental approaches for the development of vaccines for the control of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and it associated coronavirus disease 2019 (COVID-19).
Scope
Global efforts to develop vaccines recently have resulted in 3 FDA-approved vaccines candidates with excellent safety and efficacy profiles in human clinical trials that have resulted in large-scale vaccination campaigns early in 2021.Currently, RNA-based vaccines and replication defective adenovirus-based vector have been used for the treatment of COVID-19 in humans. However, additional safe and effective vaccines are needed for the treatment of SARS-CoV-2 infection and its associated COVID-19 disease.
In this section “COVID-19 vaccines and vaccination” we will consider original research and review articles, including short reports and full-size manuscripts, covering aspects related to SARS-CoV-2 vaccine development for the treatment of COVID-19 disease. These include (but not limited to) antigen selection; subunit, inactivated, and live-attenuated vaccines; approaches to enhance innate and adaptive B- and T-cell protective responses; vaccine adjuvants; delivery methods and strategies; immunological responses to SARS-CoV-2 infection or COVID-19 disease; and animal models to assess protection efficacy against SARS-CoV-2 infection and COVID-19 disease.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development (Deadline: 30 April 2024)
- Immune Effectiveness of COVID-19 Vaccines (Deadline: 30 April 2024)
- COVID Vaccines: Design, Development, and Immune Response Studies (Deadline: 31 May 2024)
- Knowledge, Attitudes and Associated Factors Surrounding COVID-19 Vaccination (Deadline: 31 May 2024)
- Knowledge, Attitudes, Beliefs and Hesitancy towards COVID-19 Vaccination and Booster Doses (Deadline: 31 May 2024)
- SARS-CoV-2 Variants, Vaccines, and Immune Responses (Deadline: 15 June 2024)
- Acute and Post-acute Sequelae of SARS-CoV-2 Infection: Focus on Systemic Complications (Deadline: 30 June 2024)
- SARS-CoV-2 Infection and Vaccines for Patients with Renal Diseases (Deadline: 30 June 2024)
- Epidemiology, Vaccinology and Surveillance of COVID-19 (Deadline: 30 June 2024)
- Understanding Immune Responses to COVID-19 Vaccines (Deadline: 31 July 2024)
- T-cell Immunity and Viral Pathogenicity on Vaccine Efficacy (Deadline: 31 July 2024)
- Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination (Deadline: 20 August 2024)
- SARS-CoV-2 Infections; Treatment and Development of Vaccine (Deadline: 20 October 2024)
- Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection against New Infections and Implication for Further Vaccination (Deadline: 31 October 2024)
- New Trends in SARS-CoV-2 Variants and Vaccines: 2nd Edition (Deadline: 30 November 2024)
- SARS-CoV-2 Infection in Women and Children (Deadline: 31 December 2024)
Topical Collection
Following topical collection within this section is currently open for submissions:
